CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Interest Cost
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Interest Cost of $11.20 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanInterestCost · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for the quarter ending 2021-12-25 was $1.46M, a 18.21% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for the quarter ending 2021-09-25 was $1.34M, a 42.93% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for the quarter ending 2021-06-26 was $1.34M, a 42.91% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for the quarter ending 2021-03-27 was $1.34M, a 42.93% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for fiscal 2025 was $11.20M, a 7.50% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for fiscal 2024 was $10.42M, a 4.79% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for fiscal 2023 was $9.94M, a 61.91% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, interest cost for fiscal 2022 was $6.14M, a 11.80% increase from fiscal 2021.
| Period end | Defined Benefit Plan, Interest Cost 3 month | Defined Benefit Plan, Interest Cost 6 month | Defined Benefit Plan, Interest Cost 9 month | Defined Benefit Plan, Interest Cost 12 month |
|---|---|---|---|---|
| 2025-12-27 | $11.20M 10-K · filed 2026-02-18 | |||
| 2024-12-28 | $10.42M 10-K · filed 2026-02-18 | |||
| 2023-12-30 | $9.94M 10-K · filed 2026-02-18 | |||
| 2022-12-31 | $6.14M 10-K · filed 2025-02-19 | |||
| 2021-12-25 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $2.80M derived: sum of 2 quarters · filed 2024-02-14 | $4.15M derived: sum of 3 quarters · filed 2024-02-14 | $5.49M 10-K · filed 2024-02-14 |
| 2021-09-25 | $1.34M 10-Q · filed 2021-11-03 | $2.69M derived: sum of 2 quarters · filed 2021-11-03 | $4.03M 10-Q · filed 2021-11-03 | $5.82M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $1.34M 10-Q · filed 2021-08-04 | $2.69M 10-Q · filed 2021-08-04 | $4.47M derived: sum of 3 quarters · filed 2023-02-22 | $6.83M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $1.34M 10-Q · filed 2021-05-04 | $3.13M derived: sum of 2 quarters · filed 2023-02-22 | $5.48M derived: sum of 3 quarters · filed 2023-02-22 | $7.84M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $4.14M derived: sum of 2 quarters · filed 2023-02-22 | $6.49M derived: sum of 3 quarters · filed 2023-02-22 | $8.85M 10-K · filed 2023-02-22 |
| 2020-09-26 | $2.35M 10-Q · filed 2021-11-03 | $4.71M derived: sum of 2 quarters · filed 2021-11-03 | $7.06M 10-Q · filed 2021-11-03 | $9.99M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $2.35M 10-Q · filed 2021-08-04 | $4.71M 10-Q · filed 2021-08-04 | $7.64M derived: sum of 3 quarters · filed 2022-02-16 | $10.54M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $2.35M 10-Q · filed 2021-05-04 | $5.29M derived: sum of 2 quarters · filed 2022-02-16 | $8.19M derived: sum of 3 quarters · filed 2022-02-16 | $11.06M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $5.83M derived: sum of 2 quarters · filed 2022-02-16 | $8.71M derived: sum of 3 quarters · filed 2022-02-16 | $11.58M 10-K · filed 2022-02-16 |
| 2019-09-28 | $2.90M 10-Q · filed 2020-10-29 | $5.78M derived: sum of 2 quarters · filed 2020-10-29 | $8.65M 10-Q · filed 2020-10-29 | |
| 2019-06-29 | $2.88M 10-Q · filed 2020-08-05 | $5.75M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $2.88M 10-Q · filed 2020-05-07 | |||
| 2018-12-29 | $10.85M 10-K · filed 2021-02-17 | |||
| 2017-12-30 | $11.64M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $12.05M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $12.97M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |